{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209020","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.571439+00:00","generated_at":"2026-06-11T19:03:02.204240+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Invivyd reports Q2 net loss $50.2M; plans pivotal VYD222 trial for COVID-19 prevention","bullets":["Net loss of $50.2M ($0.46 per share) vs. $51.0M ($0.47) in Q2 2022; revenue none.","Cash & equivalents $298.4M; runway into Q4 2024, excluding potential product revenue.","Plans to initiate CANOPY pivotal trial of VYD222 (~750 participants) using Day 28 neutralizing titers as surrogate endpoint for EUA.","Phase 1 data showed favorable safety and robust neutralizing titers against Omicron XBB.1.5 at all three doses tested.","FDA alignment on immunobridging approach for EUA; expects initial CANOPY data by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209020","json":"https://secwatch.observer/filing/0001193125-23-209020.json","markdown":"https://secwatch.observer/filing/0001193125-23-209020.md","text":"https://secwatch.observer/filing/0001193125-23-209020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312523209020/0001193125-23-209020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312523209020/d480890d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:03:02.204240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93eb0f917ea22e57952433f020ff6011edd1e8d5","claim":"Invivyd, Inc. reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Invivyd, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312523209020/0001193125-23-209020-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}